Integrated therapy for invasive bladder carcinoma. Experience with 108 patients

Area of Science:

• Urology
• Oncology
• Radiation Oncology

Background:

• Invasive bladder carcinoma (T3 stage) presents a significant clinical challenge.
• Radical cystectomy with ileal conduit urinary diversion is a standard treatment approach.
• The role of pelvic lymphadenectomy in conjunction with preoperative irradiation requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of preoperative irradiation followed by radical cystectomy without pelvic lymphadenectomy for T3 invasive bladder carcinoma.
• To determine the incidence of recurrent pelvic disease in this patient cohort.
• To assess the utility of protracted radiotherapy in potentially obviating the need for pelvic lymphadenectomy.

Main Methods:

• Retrospective review of 108 patients with clinically staged T3 invasive bladder carcinoma.
• Treatment included preoperative irradiation (5,000 rads TD/five weeks) followed by radical cystectomy and ileal conduit urinary diversion.
• Patients did not undergo pelvic lymphadenectomy.

Main Results:

• Sixty-two patients (57.4%) remain alive and disease-free between 12 and 96 months post-treatment.
• The incidence of recurrent pelvic disease was 8%.
• Protracted radiotherapy appears to be effective in managing pelvic disease, potentially reducing the need for lymphadenectomy.

Conclusions:

• Preoperative irradiation followed by radical cystectomy without pelvic lymphadenectomy is a viable treatment option for T3 invasive bladder carcinoma.
• An 8% pelvic recurrence rate suggests the effectiveness of this combined modality approach.
• Protracted radiotherapy may help identify high-risk patients who could benefit from adjuvant therapy, making pelvic lymphadenectomy less critical.